Characterization and physiotherapy evaluation of patients with Amyotrophic Lateral Sclerosis in Costa Rica
DOI:
https://doi.org/10.51481/amc.v67i2.1442Keywords:
Amyotrophic Lateral Sclerosis, Physical Therapy Services, Physical Therapy, Symptom Assessment, DemographyAbstract
Aim: To characterize the profile of individuals with amyotrophic lateral sclerosis treated at the National Center for Pain Control and Palliative Care during the 2020-2022 period, through an analysis of clinical and sociodemographic assessments.
Methods: A descriptive, cross-sectional study was conducted with a retrospective review of the medical records of patients treated in the outpatient and home care programs of the physical therapy service. All variables analyzed were related to the physiotherapy evaluation and demographic characteristics. Various tests were used to assess the patient's physical and functional status (body composition assessment using electrical bioimpedance, muscle strength measurement, and the revised Amyotrophic Lateral Sclerosis Functional Rating Scale). The presence of pain and risk of falls were also assessed. Data were obtained from the start of follow-up at the health center.
Results: The analyzed population consisted of 200 patients, 61.5% of whom were male. Patient ages at the time of assessment ranged from 30 to 89 years, although the majority were between 55 and 59 years old. Distributed by province, 44.5% of users were from San José, followed by 15.8% from Alajuela, 11.4% from Puntarenas, 7.9% from Cartago, 7.4% from Heredia, 6.4% from Guanacaste, and 6.4% from Limón. Regarding the clinical characteristics of the study population, the spinal phenotype represented the majority of cases (72%). The average time elapsed from symptom onset to diagnosis was 21 months. 62.8% of patients reported no falls. Regarding painful symptoms, 61.4% indicated that they experienced pain in some anatomical area. Using the revised amyotrophic lateral sclerosis functional rating scale, 37% of patients had involvement in all four domains (stage 5), followed by 17.4% with involvement in three domains (stage 4), 16.4% were determined to be stage 3, 16.9% were stage 2, and only 10.9% were stage 1.
Conclusion: Establishing patient profiles is important, and this study found that patients treated in the physical therapy department of this specialized national center present with advanced stages of the disease, with significant impairment in function. Furthermore, pain is a common symptom, and its location depends on the type and underlying mechanisms.
Downloads
References
1. Ghasemi M, Brown RH Jr. Genética de la esclerosis lateral amiotrófica. Cold Spring Harb Perspect Med. 2018; 8: a024125. DOI:10.1101/cshperspect
2. Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 20: 413-420. DOI: 10.1080/21678421.2019.1612435
3. Bento D da CP, Oliveira RPD de, Santos K de F, Azevedo RM, Minasi LB, Ternes YMF, et al. Características clínicas y epidemiológicas de pacientes com Esclerose Lateral Amiotrófica (ELA) no Brasil Central. Medicina (Ribeirão Preto). 2022; 55: e-192620. DOI: 10.11606/issn.2176-7262.rmrp.2022.192620
4. Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., et al. Prognostic factors in ALS: A critical review. Amyotrophic Lateral Scler 2009; 10: 310-23. DOI: 10.3109/17482960802566824
5. Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, et al. Amyotrophic lateral sclerosis. Lancet. 2002; 15: 2363-1380. DOI: 10.1016/S0140-6736(22)01272-7
6. Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 201932; 771-776. DOI: 10.1097/WCO.0000000000000730
7. Martínez HR. Acelerar el diagnóstico de esclerosis lateral amiotrófica utilizando los criterios Gold Coast y biomarcadores. Rev Mex Neuroci. 2023; 24: 93-98. DOI: 10.24875/rmn.22000076
8. Bucheli M, Campos M, Bermúdez DB, Chuquimarca JP, Sambache K, Niato JF, et al. Esclerosis lateral amiotrófica: revisión de evidencia médica para tratamiento. Rev. Ecuat. Neurol, 2013; 22: 68-76.
9. Cañadilla Barrios Y, Mesa Anoceto M, Bosque Jiménez J, Vidaurreta Bueno R, Cañete Rojas AC. Evaluación de diseño de un programa de ejercicios físico-terapéuticos para pacientes con esclerosis lateral amiotrófica. Rev Podium. 2021; 16: 772-782.
10. Gaitan SA, Chaustre DM. Rehabilitación basada en ejercicio físico en pacientes con esclerosis lateral amiotrófica. Rev Col Med Fis Rehab. 2024; 34: e413. DOI: 10.28957/rcmfr.413
11. González N, Escobar E, Escamilla C. Esclerosis lateral amiotrófica. Monografía. Rev. Mex. Med. Fís. y Rehab. 2003; 15: 44-54.
12. Calderón-Sepúlveda RF. Escalas de medición de la función motora y la espasticidad en parálisis cerebral. Rev Mex Neuroci. 2002; 3: 285-289.
13. Leiva A, González F, Fernandéz R, Ostolaza M, Sivori M. Escala revisada de valoración funcional de esclerosis lateral amiotrófica: adaptación transcultural. Medicina (B. Aires). 2022; 82: 525-533.
14. Campos TS, Rodríguez-Santos F, Esteban J, Vázquez PC, Mora Pardina JS, Carmona AC. Spanish adaptation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Amyotroph Lateral Scler. 2010; 11: 475-477. DOI: 10.3109/17482968.2010.489115
15. Ortiz Corredor F, Mendoza Pulido C, Peña Preciado M. Diseño de un sistema de clasificación para evaluar el grado de discapacidad en pacientes con esclerosis lateral amiotrófica. Rev. Colomb. Med. Fis. Rehabil. 2011; 21:14-22.
16. Vicente-Herrero M.T., Delgado-Bueno S., Bandrés-Moyá F., Ramírez-Iñiguez-de-la-Torre M.V., Capdevilla-García L.. Valoración del dolor. Revisión comparativa de escalas y cuestionarios. Rev. Soc. Esp. Dolor. 2018; 25: 228-236. DOI: 10.20986/resed.2018.3632/2017
17. Espinosa-Cuervo G, López-Roldán VM, Escobar-Rodríguez DA, Conde-Embarcadero M, Trejo-León G, González-Carmona B. Gait, balance and independence rehabilitation program in elderly adults in a primary care unit. Rev Med Inst Mex Seguro Soc. 2013; 51:562-573.
18. Monzón AM. Evaluación del test Timed Up And Go en adultos mayores. AJRPT. 2022; 4: 55–59. DOI: 10.58172/ajrpt.v4i2.225
19. Abadía-Cubillo K, Díaz-Cascante C, Granados-Acuña C, Castro-Cordero J, Salas-Herrera I. Efectos del riluzol en la evolución clínica y sobrevida de los pacientes con esclerosis lateral amiotrófica en Costa Rica. Acta méd. costarric. 2005; 57: 172-178. DOI: 10.51481/amc.v57i4.898
20. Alfaro-Campos GC, Ulate-Gómez D. Prevalencia de Esclerosis Lateral Amiotrófica en Costa Rica. Revista Terapéutica. 2022; 16: 79-85. DOI: 10.33967/rt.v16i1.141
21. Zhou S, Zhou Y, Qian S, Chang W, Wang L, Fan D. Amyotrophic lateral sclerosis in Beijing: Epidemiologic features and prognosis from 2010 to 2015. Brain and Behavior 2018; 8: e01131. DOI: 10.1002/brb3.1131
22. Epps D, Kwan JY, Russell JW, Thomas T, Diaz-Abad M. Evaluación y tratamiento de la disfagia en la esclerosis lateral amiotrófica: una encuesta sobre la práctica clínica de los patólogos del habla y el lenguaje. J Clin Neuromuscul Dis. 2020; 21: 135-141. DOI: 10.1097/CND.00000000000000281
23. Zarco-Martín MT, Freire C, Andreo-López MC, Leyva-Martínez S, Fernández-Soto ML. Malnutrition in Amyotrophic Lateral Sclerosis: Insights from Morphofunctional Assessment and Global Leadership Initiative on Malnutrition Criteria. Nutrients. 2024; 16:2625. DOI: 10.3390/nu16162625.
24. López-Gómez JJ, Izaola-Jauregui O, Almansa-Ruiz L, Jiménez-Sahagún R, Primo-Martín D, Pedraza-Hueso MI, et al. Ultrasonography in Morphofunctional Assessment of Amyotrophic Lateral Sclerosis (ALS). Nutrients. 2024; 16: 1021. DOI: 10.3390/nu16071021
25. Shell WE, Mar VS, DaSilva CPCorrelation of falls in patients with Amyotrophic Lateral Sclerosis with objective measures of balance, strength, and spasticity. NeuroRehabilitation. 2019; 44: 85-93. DOI: 10.3233/NRE-182531
26. Gatti MA, Broggi MS, Rivas ME, Muzio D, Bonetto M, Alessandro L. Desempeño físico en pacientes con esclerosis lateral amiotrófica y su relación con el uso de silla de ruedas y ayuda para la marcha. Rehabilitación (Madr). 2022; 54; 279-283. DOI: 10.1016/j.rh.2022.03.003
27. Chiò A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017; 16: 144-157. DOI: 10.1016/S1474-4422(16)30358-1
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
